stockrowBio-Rad Laboratories, Inc.
BIO Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO
Alert me
Bio-Rad Laboratories, Inc. (BIO) Total debt
Bio-Rad Laboratories, Inc.'s total debt at the end of fiscal 2025 was $1.2B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $1.2B. Over the past ten years it has ranged from $11.0M (fiscal 2021) to $1.2B (fiscal 2025) — the current reading is the highest in ten years. Bio-Rad Laboratories, Inc. ranks 17th of 147 Medical Devices companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $1.2B | 0.12% |
| FY2024 | $1.2B | 0.17% |
| FY2023 | $1.2B | 0.12% |
| FY2022 | $1.2B | 10,789.58% |
| FY2021 | $11.0M | (21.72%) |
| FY2020 | $14.1M | (96.80%) |
| FY2019 | $439.8M | 0.07% |
| FY2018 | $439.4M | 1.02% |
| FY2017 | $435.0M | 0.19% |
| FY2016 | $434.2M | 0.07% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $1.2B | 0.02% |
| Jun 2026 | $1.2B | 0.02% |
| Mar 2026 | $1.2B | 0.03% |
| Dec 2025 | $1.2B | 0.02% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $3.2B |
| BRKR Bruker Corporation compare | $1.7B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $1.2B |
| BIO Bio-Rad Laboratories, Inc. | $1.2B |
| PODD Insulet Corporation compare | $962.1M |
| GMED Globus Medical, Inc. compare | $443.4M |
| TXG 10x Genomics compare | $98.0M |
| GKOS Glaukos Corporation compare | $66.9M |
| PEN Penumbra, Inc. compare | $19.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on BIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement